2CV Stock Chart & Stats
CHF2.37
--
―
--
Day’s Range― - ―
52-Week RangeCHF2.37 - CHF2.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
CHF4.59B
Enterprise ValueCHF6.06K
Total Cash (Recent Filing)CHF75.03M
Total Debt (Recent Filing)CHF1.52B
Price to Earnings (P/E)33.4
Beta2.25
Next Earnings
Aug 04, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF3.30Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)<0.01
Revenue Forecast (FY)CHF27.88M
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthSustained mid-single-digit organic growth across core chronic-care categories indicates durable demand and successful product adoption. Management's 5–7% guidance (ex-InnovaMatrix) and a 6–8% medium-term target reflect structural revenue drivers from recurring consumables, new launches and expanding non-diabetes infusion share that support multi-year topline resilience.
Operating Margin Expansion And TargetsMaterial and sustained operating-margin improvement suggests structural cost and pricing discipline (productivity, simplification, price) and operating leverage as revenue scales. Management's mid-20s margin ambition implies margins are not a one-off, underpinning durable profitability that can fund investment and returns while absorbing moderate inflationary pressure.
Strong Cash Generation And Disciplined Capital ReturnsConsistently high free-cash-flow conversion and active buybacks/dividend growth signal robust cash conversion from operations. Reliable FCF supports reinvestment in capacity and the rich product pipeline while enabling shareholder returns, reducing reliance on external financing and improving long-term capital allocation flexibility.
Bears Say
InnovaMatrix Reimbursement Shock And ImpairmentA major reimbursement-driven price cut and subsequent impairment demonstrate structural vulnerability to payor policy for acquired products. This can permanently depress revenue from the product, reduce acquisition economics, and create ongoing channel and legal uncertainty, limiting the company's ability to rely on acquisitions for durable growth.
FDA Warning Letter On Complaints And CAPARegulatory-process deficiencies are a durable operational risk: remediation may require systemic changes, higher compliance costs, slower product introductions and potential enforcement. Persistent quality-system weaknesses can damage provider trust and reimbursement relationships, constraining sustainable sales growth in regulated healthcare markets.
Increased Leverage Reducing Financial FlexibilityRising leverage and higher net debt increase sensitivity to interest rates and reduce financial slack for opportunistic M&A or shock absorption. Even with targets to manage leverage (~2x net debt/EBITDA), the step-up in debt limits flexibility to fund growth or withstand reimbursement or execution setbacks without constraining investment or capital-return plans.
ConvaTec News
2CV FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was CHF2.37 and its highest was CHF2.37 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is CHF4.59B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 15 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported CHF0.078 earnings per share for the quarter, missing the consensus estimate of CHF0.081 by -CHF0.002.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec does not currently pay dividends.
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.07.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of CHF0.078 in its last earnings report, missing expectations of CHF0.081. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in CH:2CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF3.30 (― Downside)
CHF3.30 (― Downside)
Insider Transactions
Bought Shares
Worth CHF163.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
2.45%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
2CV Stock 12 Month Forecast
Average Price Target
CHF3.30